Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.
about
"How many times must a man look up before he can really see the sky?" Rheumatic cardiovascular disease in the era of multimodality imaging.New SPECT and PET radiopharmaceuticals for imaging cardiovascular diseaseAdvanced tracers in PET imaging of cardiovascular diseaseSPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular diseaseClinical Utility and Future Applications of PET/CT and PET/CMR in Cardiology.Nuclear cardiology: 2014 innovations and developmentsMitochondrial-Targeted Molecular Imaging in Cardiac DiseaseAbsolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PETCardiac PET perfusion tracers: current status and future directions.CFR and FFR assessment with PET and CTA: strengths and limitations.Myocardial perfusion imaging with PETStart from Scratch: the Prospect of Nuclear CardiologySynthesis and Evaluation of (18)F-labeled Pyridaben Analogues for Myocardial Perfusion Imaging in Mice, Rats and Chinese mini-swine.Biological characterization of F-18-labeled rhodamine B, a potential positron emission tomography perfusion tracer.Pet Imaging and its Application in Cardiovascular Diseases.Diagnosing coronary artery disease with hybrid PET/CT: it takes two to tango.Coronary microvascular dysfunction: mechanisms and functional assessment.Radionuclide myocardial perfusion imaging for the evaluation of patients with known or suspected coronary artery disease in the era of multimodality cardiovascular imaging.Cardiac PET for translational imaging.Stress echocardiography: what is new and how does it compare with myocardial perfusion imaging and other modalities?Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.Research Progress on 18F-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography.Assessing time-of-flight signal-to-noise ratio gains within the myocardium and subsequent reductions in administered activity in cardiac PET studies.PET/MR: Yet another Tesla?Recent Advances in Nuclear CardiologyAbsolute quantification of myocardial blood flow.Impact of motion and partial volume effects correction on PET myocardial perfusion imaging using simultaneous PET-MR.PET imaging in heart failure: the role of new tracers.The role of PET quantification in cardiovascular imaging.Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?(18)F-labeled rhodamines as potential myocardial perfusion agents: comparison of pharmacokinetic properties of several rhodamines.Value of Hybrid Imaging with PET/CT to Guide Percutaneous Revascularization of Chronic Total Coronary OcclusionAssociation of coronary plaque burden with fractional flow reserve: should we keep attempting to derive physiology from anatomy?PET should replace SPECT in cardiac imaging for diagnosis and risk assessment of patients with known or suspected CAD: Pro.Beyond ultrasound: advances in multimodality cardiac imaging.Role of Cardiac PET in Clinical Practice.Radiopharmaceutical tracers for cardiac imaging.New chemical and radiochemical routes to [18F]Rho6G-DEG-F, a delocalized lipophilic cation for myocardial perfusion imaging with PET.Advances in imaging instrumentation for nuclear cardiology.Quantitative Assessment of Coronary Microvascular Function: Dynamic Single-Photon Emission Computed Tomography, Positron Emission Tomography, Ultrasound, Computed Tomography, and Magnetic Resonance Imaging.
P2860
Q26785666-813638D1-087D-44A8-AFE6-9F9FBBC80F49Q27011866-9993631A-72AA-4789-8700-E552C5DD5D51Q27023690-7026FC64-3ED0-4C0B-BAB4-17E7687755B0Q28066121-85131604-283F-4589-A4CC-A329DAA793BDQ28073135-E3976E7E-7480-489C-AE43-764BB3FA8F8DQ28081835-6CED6ABA-4083-47DB-BD91-30275B6BF959Q33790688-533AFA9C-2856-444C-9CB2-F7BE401F504DQ35044167-2A0FF880-B1ED-48BC-B176-7A034EF995A9Q35097258-8938E041-2AE7-4706-A561-F902024048C5Q36081581-30246CB8-423C-4B3C-8D89-ABAC28853401Q36834147-32032F63-E686-4B5D-BC7D-05F2875BC8DCQ36910290-A3C26C09-4C51-4FFF-9BE2-6D635680607EQ37267327-02520C09-926D-4E25-88C7-F92956D3953EQ37287803-5E6FE1BC-63F1-4392-84B8-941CEB8CCD0BQ37743798-E3B81158-209E-401F-B294-1A00EF8E24FCQ38120658-3515E0EB-7D0A-4A1F-B22D-34FAA0A03CEAQ38259726-41F0E27F-A4A5-403D-AC2E-C05E688BD9C9Q38377656-B8D8BF94-8597-46D0-A1DD-BFCDE425FEF3Q38430736-80F3F684-18F6-46D3-89C6-E317A5066105Q38441632-7685C51F-73FE-4B75-9707-347C13031A22Q38670162-4DB1B81F-3F93-4599-894D-158B456DE9DCQ38737734-2A3AA308-A03D-44C9-B495-45D3F84B253EQ38790061-C0512956-4D7F-47DE-8AAC-9BFD886A3A20Q38818563-47C9D8EA-25D0-48A2-8241-A73B9BB40A0FQ38829878-53AA9736-E8CC-4090-BB87-7335E5AE2A06Q38905038-1138E400-56D8-4513-A960-A694E9CD6480Q39083985-D5B6AA7F-6150-4376-A25C-8C61C2B6E5E2Q39285234-D6261822-01E1-47DB-B218-7D9B537EEBE4Q40655323-CA26EB63-06FC-470C-84A5-27157CCE043FQ41871815-428A7C52-020C-4D69-A89C-6C79059B26E9Q42135474-28DCFB4A-4C9D-4CE8-8217-71243E593074Q42535948-CB484AE8-9230-422B-B209-16F5024D1BF4Q43147789-822DAB5F-575F-412A-A2A1-C4F3E15E6112Q43658240-201941E6-AB1D-4113-ACD8-70FB1E871326Q46195604-7B3ED077-B6E0-42D1-B884-35BA9CB4889AQ47628378-AA8BABC7-4493-4F55-99C8-1B7B10E9AD51Q49352380-8DF637EE-9F1C-47EC-B2E4-208F336BE7A9Q49585267-E9F8E3FE-AADE-4FF3-997F-DBDE391C342AQ50526937-5EE2E423-BADB-4213-8611-7401D9C4E3B6Q52936656-2CDD5818-DFE2-4E6E-B182-2BC10BBC1FEF
P2860
Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase II safety and clinical c ...... positron emission tomography.
@en
type
label
Phase II safety and clinical c ...... positron emission tomography.
@en
prefLabel
Phase II safety and clinical c ...... positron emission tomography.
@en
P2093
P2860
P1476
Phase II safety and clinical c ...... positron emission tomography.
@en
P2093
B K Tamarappoo
C Michael Gibson
Dana Washburn
Daniel S Berman
Gajanan Bhat
James E Udelson
Jamshid Maddahi
Joel Lazewatsky
Johannes Czernin
Marybeth Devine
P2860
P304
P356
10.1016/J.JACC.2012.11.022
P407
P577
2012-12-19T00:00:00Z